Related Experiment Video

Updated: Jul 6, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

[Therapeutic possibilities in patients with selective pituitary resistance to thyroid hormones]

Pedro Iglesias1, Juan José Díez

  • 1Servicio de Endocrinología, Hospital General, Segovia, España. piglesias@hgse.sacyl.es

Medicina Clinica
|April 1, 2008
PubMed

Insights

Selective pituitary resistance to thyroid hormones (SPRTH) involves inactivating mutations in the TR-beta gene, leading to elevated thyroid hormones without suppressed TSH. Current treatments focus on symptom management, with TR agonists showing potential for reducing TSH secretion.

Area of Science:

  • Endocrinology
  • Molecular Genetics
  • Hormone Physiology

Background:

  • Selective pituitary resistance to thyroid hormones (SPRTH) is a rare endocrine disorder characterized by inappropriate thyrotropin (TSH) secretion.
  • It stems from inactivating mutations in the thyroid hormone receptor beta (TR-beta) gene, specifically affecting the T3-binding domain.
  • Clinical presentation includes hyperthyroidism with goiter but no pituitary mass.

Purpose of the Study:

  • To elucidate the genetic basis and clinical characteristics of SPRTH.
  • To review current therapeutic strategies and explore potential treatments for managing TSH secretion.

Main Methods:

  • Genetic analysis of the TR-beta gene in affected individuals.
  • Review of clinical and laboratory findings in SPRTH patients.
  • Literature review of therapeutic interventions for SPRTH.

Main Results:

  • Inactivating mutations in the TR-beta gene are identified as the cause of SPRTH.
  • Laboratory results show elevated free T3 and free thyroxine with non-suppressed TSH and a normal alpha/TSH molar subunit ratio.
  • No specific cure exists; symptomatic treatments like beta-blockers and benzodiazepines are used.

Conclusions:

  • SPRTH is a distinct entity caused by TR-beta gene mutations.
  • TR agonists represent a promising therapeutic avenue for reducing TSH secretion in SPRTH.
  • Further research into targeted therapies is warranted.

Related Concept Videos

Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...